A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 148 (final count)
- Started
- Dec 19, 2023
- Main results expected
- Nov 2, 2035
- Fully finished
- Nov 2, 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose-Limiting Toxicities (DLTs)
Measured over: End of the Observation period; up to day 28
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Post-Last Linvoseltamab Dose, up to 90 days
Severity of TEAEs
Measured over: Post-Last Linvoseltamab Dose, up to 90 days
Incidence of Adverse Events of Special Interest (AESIs)
Measured over: Post-Last Linvoseltamab Dose, up to 90 days
Severity of AESIs
Measured over: Post-Last Linvoseltamab Dose, up to 90 days
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Measured over: Up to 5 years
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Measured over: Up to 5 years
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Measured over: Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Measured over: Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Measured over: Up to 5 years
Changes Tremor has spotted
Status changed: Signing up patients → Running, no new patients. Usually normal progress.
Spotted
Slightly lowered the number of patients, from 149 to 148.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · status_changed · overall_status
old: "RECRUITING"
new: "ACTIVE_NOT_RECRUITING" - 2026-11-06 15:29 UTC · enrollment_small_cut · enrollment
old: 149
new: 148
details: {"new_type":"ACTUAL","old_type":"ESTIMATED","percent_cut":0.7}
Trial ID NCT05828511 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC